Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial
Thiery-Vuillemin, A. Saad, F. Armstrong, A. J. Oya, M. Vianna, K. Özgüroglu, M. Gedye, C. Buchschacher, G. L. Lee, J. Y. Emmenegger, U.
Thiery-Vuillemin, A.
Saad, F.
Armstrong, A. J.
Oya, M.
Vianna, K.
Özgüroglu, M.
Gedye, C.
Buchschacher, G. L.
Lee, J. Y.
Emmenegger, U.
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Thiery-Vuillemin A, Saad F, Armstrong AJ, Oya M, Vianna K, Özgüroglu M, et al. Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772001099.